Search company, investor...

Zyto Group

Stage

Acq - Fin | Alive

About Zyto Group

Zyto Group is a fully integrated developer, manufacturer, and distributor of in-situ hybridization (ISH) and immunohistochemistry (IHC) cancer diagnostics tests and equipment for clinical pathology labs in hospitals and private practices. It is based in Germany.

Headquarters Location

Bremerhaven,

Germany

Missing: Zyto Group's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Zyto Group's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Zyto Group Patents

Zyto Group has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/13/2006

1/17/2012

Diving medicine, Physiology, Underwater diving physics, Educational psychology, Ethology

Grant

Application Date

9/13/2006

Grant Date

1/17/2012

Title

Related Topics

Diving medicine, Physiology, Underwater diving physics, Educational psychology, Ethology

Status

Grant

Latest Zyto Group News

Germany: ArchiMed takes majority stake in Zyto

Jan 20, 2021

LaingBuisson News By Financial terms have not been disclosed. Zyto’s three operating companies – Zytomed, ZytoVision and 42 Life Sciences – provide doctors with diagnostic tools to understand the genetic changes that occur in individual patients’ tumours. The approach permits precision medical treatment, in which doctors create more effective, customised care based on a genetic understanding of how disease is evolving in individual patients. “Our internal expertise – a majority of ArchiMed team members have science backgrounds and many have operational experience in medical or pathology labs – was key to understanding the potential of Zyto’s complex, industry-leading products,” said ArchiMed managing partner Vincent Guillaumot. “With our backing, these companies have the resources for further product innovation and for rapid international expansion,” he added. ArchiMed is acquiring its stake via its MED II fund, which closed on €315m (US$384.4m) in 2017. The Zyto investment, financed with equity and debt, is ArchiMed’s third transaction in the diagnostics industry in the last 24 months. It follows the carve-out from Poland’s Cormay of Diesse Diagnostica Senese, an Italian developer of innovative in vitro diagnostic systems (and a leading developer and manufacturer of a proprietary Covid-19 test) in May 2019 and the acquisition of Austria-based point-of-care diagnostics group EUROLyser and its distributor, EuroLab in February 2019.

Zyto Group Frequently Asked Questions (FAQ)

  • Where is Zyto Group's headquarters?

    Zyto Group's headquarters is located at Bremerhaven.

  • What is Zyto Group's latest funding round?

    Zyto Group's latest funding round is Acq - Fin.

  • Who are the investors of Zyto Group?

    Investors of Zyto Group include ArchiMed.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.